The numbered sources lead to the original work
Retatrutide references name the reports behind the findings
A claim about weight can make you want the original report. These sources name who did the work. The links lead to their papers and study details.
Match the number beside a finding to its report
A number beside a finding helps you find its source below. Each entry names the authors, journal and year. Links open the report or ClinicalTrials.gov, a public list of studies.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
- Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
- Eli Lilly and Company. A Study of Retatrutide (LY3437943) Once Weekly in Participants With Obesity and Type 2 Diabetes (TRIUMPH-2). ClinicalTrials.gov. 2023. ↗
- Eli Lilly and Company. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Function. ClinicalTrials.gov. 2024. ↗
- Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176). ClinicalTrials.gov. 2024. ↗
- Eli Lilly and Company. A Study of LY3437943 in Healthy Participants. ClinicalTrials.gov. 2019. ↗
- Bhat S, et al. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World Journal of Cardiology. 2025;17(8):107991. ↗
- Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a randomised, double-blind, placebo- and active-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2025. ↗
- The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes or Overweight/Obesity. Kidney Int Rep. 2025. ↗
- Pearson MJ, et al. Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. ↗
- Wen Y, et al. Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. Diabetes Obes Metab. 2025. ↗